Christopher Mutz, who serves as Head of Rare Disease at ANI Pharmaceuticals Inc. (NASDAQ: ANIP), completed a sale of common stock on March 2, 2026, disposing of 417 shares at $74 per share. The transaction generated $30,858 in proceeds and was executed while ANIP shares were trading in the vicinity of $76.53.
Following the sale, Mutz directly holds 103,508 shares of the company's common stock. The disposition was carried out pursuant to a Rule 10b5-1 trading plan that Mutz adopted on June 16, 2025.
ANI Pharmaceuticals has been reporting strong operating results. The company is noted in company disclosures for 44% revenue growth and a market capitalization of $1.6 billion. Recent quarterly results for the fourth quarter of 2025 reinforced that performance: ANI posted earnings per share of $2.33, versus a consensus forecast of $1.97 - an 18.27% positive surprise. Revenue for the quarter came in at $247.1 million, ahead of the $232.37 million analysts had anticipated.
Despite the upside in quarterly results, the stock registered a slight decline in premarket trading. There were no announcements tied to mergers or acquisitions linked to the company, and analyst firms have not recently issued upgrades or downgrades on the stock, according to the same report.
Separately, analysis available through InvestingPro indicates ANIP appears undervalued at current levels, with analysts projecting earnings per share of $9.41 for fiscal year 2026. InvestingPro's Pro Research Report is cited as a source of further detail on the company's projected trajectory.
Summary of the transaction and company context:
- Insider sale: Christopher Mutz sold 417 shares at $74 on March 2, 2026, for $30,858.
- Ownership after sale: Mutz holds 103,508 shares directly.
- Trading plan: The sale was executed under a Rule 10b5-1 plan adopted June 16, 2025.
- Company performance: ANI reported 44% revenue growth, a market cap of $1.6 billion, Q4 2025 EPS of $2.33 (vs. $1.97 expected) and revenue of $247.1 million (vs. $232.37 million expected).